2003 ISPOR Short Course Task Force Committee
| |
Short Course Development & Quality Assurance
Task Force Chair: |
| |
Lorne Basskin PharmD,
President, Trinka Publications, Cooper City, FL, USA |
| |
Committee Members: |
| |
Bernard Bloom PhD, Research Professor,
University of Pennsylvania, Philadelphia, PA, US; |
| |
J. Jaime Caro MD, Scientific Director, Caro
Research, Concord, MA, USA |
| |
Michael Schaffer PharmD, Director of Health
Policy & Clinical Outcomes, Health Partners, Philadelphia, PA, USA |
| |
Tina Shih PhD,
Associate Professor, University of Texas, MD Anderson
Cancer Center, TX, USA |
| |
Jenny Sung PharmD, MS, Outcomes Research,
Associate Director,
Novartis, East Hanover, NJ, USA |
| |
Michael Wall PharmD, Fellow, Pfizer/University
of Michigan, Ann Arbor, MI, USA |
ISPOR Short Course
Educational Objectives:
ISPOR Short Courses are provided to enhance the development of
individuals involved in pharmacoeconomics and outcomes research or who
use this research in health care decision-making. Faculties, who have
published in the specific discipline, present these courses. Each
participant receives a course syllabus/workbook and an ISPOR
Certificate of Completion. The participant will learn new
methodologies and outcomes research techniques, improve skills in the
specific course subject selected, and be able to apply learned skills
to his/her specific work environment. |
9:00am – 5:00pm
Introduction to
Pharmacoeconomics
Faculty: Lorne Basskin PharmD,
President, Trinka Publications, Cooper City, FL, USA
Course Description: This one-day short course
is designed to teach clinicians and new researchers how to incorporate
pharmacoeconomics into study design and data analysis. Participants will
learn how to collect and calculate the costs of different alternatives,
determine the economic impact of clinical outcomes, and how to identify,
track and assign costs to different types of health care resources used. The
development of economic protocols and data collection sheets will be
discussed. Different pharmacoeconomic models and techniques will be
demonstrated and practiced in lectures and case studies. These include
cost-minimization, cost-of-illness, cost-effectiveness, cost-benefit, and
cost-utility analysis. Decision analysis, sensitivity analysis, and
discounting, will all be demonstrated and practiced. Participants will also
learn to compare and evaluate interventions such as drugs, devices and
clinical services. This course is suitable for those with little or some
experience with pharmacoeconomics.
Advanced Statistical Methods for
Retrospective Database Analyses (8 hours)
Faculty: Thomas E. Delea MBA, Senior
Consultant, PAI, Brookline, MA, USA; Derek Weycker PhD, Senior Consultant, PAI, Brookline, MA, USA.
Course Description: Large administrative claims
databases provide a unique opportunity to examine retrospectively the
effects of drug use on clinical and economic outcomes in "real world"
settings. This course will examine analytical approaches that may be used
for estimating the relationship between drug use and clinical and economic
outcomes using administrative databases, as well as the challenges
associated with such analyses, in particular confounding (i.e., selection
bias) and censoring. Analytical approaches to be covered will include OLS,
logistic, and Poisson regression, survival analysis, and the Kaplan-Meier
Sample Average (KMSA) method. Also discussed will be the use of propensity
scores, instrumental variables, and nonparametric bootstrapping, as well as
methods for selection of model covariates and testing of model assumptions.
Course participants will be required to apply these methods in formal
classroom exercises. This advanced-level course will assume participants
have knowledge of statistical methods and/or econometrics and experience in
the analysis of administrative claims databases.
Prospective Economic Trials: Computer-assisted
Applications
Faculty:
Andrew Briggs PhD, Health Economics Research Centre,
University of Oxford, Institute of Health Sciences, Oxford, UK; John Cook
PhD, Director, Merck Research Laboratories, Blue Bell, PA, USA; Henry
Glick PhD, Health Economist, University of Pennsylvania, Philadelphia,
PA, USA
Course Description: Randomized controlled
trials are the accepted standard for demonstrating the efficacy and safety
of new pharmaceuticals. They also can be a useful venue for collecting
economic data. This course will provide participants with an overview of
methodologic and practical issues surrounding economic data collection that
is "piggybacked" onto otherwise-traditional randomized controlled trials,
including protocol development, data collection, and data analysis. The
course also will consider circumstances under which such studies do not
provide an appropriate setting for collecting "real-world" economic data,
and will discuss key aspects of clinical trials that are conducted
specifically to inform economic decision making ("pragmatic clinical
trials") as well as issues in the design and conduct of these types of
investigations. Course participants will be asked to solve specific problems
in the design of trial-based economic investigations. Participants will also
use computer software to analyze data from a real prospective study. This
course is designed for persons with a basic knowledge of and familiarity
with clinical trial methodology as well as techniques of economic
investigation. Each participant must bring a laptop computer.
|